The Spasmodic Torticollis (Cervical Dystonia) drugs in development market research report provides comprehensive information on the therapeutics under development for Spasmodic Torticollis (Cervical Dystonia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Spasmodic Torticollis (Cervical Dystonia). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Spasmodic Torticollis (Cervical Dystonia) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Spasmodic Torticollis (Cervical Dystonia) by seven companies/universities/institutes. The top development phase for Spasmodic Torticollis (Cervical Dystonia) is preclinical with two drugs in that stage. The Spasmodic Torticollis (Cervical Dystonia) pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Spasmodic Torticollis (Cervical Dystonia) pipeline products market are: Viatris, AEON Biopharma and Addex Therapeutics.
The key targets in the Spasmodic Torticollis (Cervical Dystonia) pipeline products market include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25), and Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5).
The key mechanisms of action in the Spasmodic Torticollis (Cervical Dystonia) pipeline product include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor with five drugs in Pre-Registration. The Spasmodic Torticollis (Cervical Dystonia) pipeline products include six routes of administration with the top ROA being Intramuscular and three key molecule types in the Spasmodic Torticollis (Cervical Dystonia) pipeline products market including Protein, and Recombinant Protein.
Spasmodic Torticollis (Cervical Dystonia) overview
Cervical dystonia, also known as spasmodic torticollis, is a rare neurological disorder that originates in the brain. It is the most common form of focal dystonia in an office setting. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head
For a complete picture of Spasmodic Torticollis (Cervical Dystonia)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
